Clinical trial
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic…
NCT00053001 · Fallon Clinic, Industry · Completed
Key facts
| NCT number | NCT00053001 |
|---|---|
| Title | Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome |
| Official title | A Phase II Study on the Effectiveness of Thalomid (Thalidomide) Combined With Procrit (Erythropoietin) for the Treatment of Anemia in Patients With Low and Intermediate Risk-1 (IPSS Score Less Than or Equal to 1.5) Myelodysplastic Syndromes |
| Lead sponsor | Fallon Clinic, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Biological, Drug |
| Interventions | epoetin alfa, thalidomide |
| Start date | Jun 1, 2001 |
| Completion | Oct 1, 2007 |
| First posted | Jan 28, 2003 |
| Last update posted | Jun 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: